View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 2, 2020updated 12 Jul 2022 11:39am

Biophytis starts Phase II/III Covid-19 trial of Sarconeos in Belgium

Biotechnology firm Biophytis has started enrolment and dosing of patients in a Phase II/III clinical trial to assess Sarconeos (BIO101) for treating respiratory failure due to Covid-19.

Biotechnology firm Biophytis has started enrolment and dosing of patients in a Phase II/III clinical trial to assess Sarconeos (BIO101) for treating respiratory failure due to Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The first participant was dosed at AZ Sint Maarten hospital in Mechelen, Belgium.

Named COVA, the trial currently has five centres active for enrolment in Belgium, France and the US. It will also be performed in Brazil and the UK.

The multi-national, randomised, double-blind, placebo-controlled, adaptive and group sequential Phase II/III trial will investigate the safety and efficacy of Sarconeos in preventing further respiratory deterioration in patients with severe respiratory failure.

During the first portion of the two-part study, the drug candidate will be evaluated for its treatment safety and anti-viral activity in 50 hospitalised Covid-19 patients with acute respiratory deficiency.

The second portion will assess Sarconeos’ efficacy on the respiratory function in an additional 260 patients. The trial aims to enrol a total of approximately 310 patients.

Primary endpoint of the trial is the proportion of all-cause mortality and respiratory deterioration within up to a 28-day period.

Secondary endpoints include improvement, worsening and hospital discharge, functional scales and the biomarkers of Sarconeos mechanism of action and inflammation.

Biophytis CEO Stanislas Veillet said: “Whilst in many countries Covid-19 has continued its steady spread, in Europe we are seeing again a worrying increase of new Covid-19 cases.

“With physicians still in need of effective treatments for Covid-19-related respiratory failure, we believe Sarconeos (BIO101) has the potential to serve as a differentiated treatment option for patients with severe respiratory manifestations.”

In July this year, Biophytis partnered with contract research organisation (CRO) SGS to study Sarconeos as a treatment for Covid-19-related respiratory failure.

SGS secured regulatory approval from Belgium’s Federal Agency for Medicines and Health Products (FAMHP) to conduct the COVA study.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena